Ginkgo Bioworks Holdings Inc Dossier - Source-backed chat

Ginkgo Bioworks Holdings Inc

DNANYSE

SectorHealth Care

IndustryLife Sciences Tools & Services

Beta (adjusted)1.52

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $12.50Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $841.8M

Enterprise Value $757.2M

Shares Outstanding 67.3M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Ginkgo Bioworks is undergoing a high-stakes strategic pivot towards AI-driven autonomous labs (Nebula) following the divestiture of its non-core Biosecurity business in April 2026. While the long-term vision of automated biology is compelling, the company faces severe near-term headwinds. Revenue from continuing operations has contracted sharply (down 49% YoY in Q1 2026 to $19 million) due to ongoing program rationalization. Despite aggressive restructuring and cost-cutting, GAAP losses remain substantial ($76 million in Q1 2026), and the business continues to burn significant cash. With an unproven monetization model for its capital-intensive autonomous lab infrastructure and highly polarized Wall Street sentiment, a cautious stance is warranted.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$8.50

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0030%

The transition to autonomous labs fails to generate expected customer demand, and external system sales do not materialize. Technical reliability issues emerge as Nebula scales, while excess lease space liabilities continue to drag on financial performance. Cash burn exceeds expectations, rapidly depleting the company's $373 million cash reserve and forcing dilutive equity raises under the ATM program, leading to further downside.

Base CaseCentral scenario

$8.5050%

Matches the consensus mean

Ginkgo slowly transitions its R&D services onto the Nebula platform while decommissioning traditional lab benches. Revenue remains pressured in the near term as old programs are rationalized, stabilizing slowly in late 2026 or 2027. Cash burn is managed within the guided range of $125-$150 million, but the path to GAAP profitability remains distant and highly dependent on proving the efficiency gains of autonomous labs to skeptical customers.

Bull CaseUpside scenario

$12.0020%

Monetization of the Nebula autonomous lab platform accelerates rapidly. Ginkgo successfully signs multiple high-value external system sales with biopharma, national labs, and research universities. The Cloud Lab and Datapoints services gain rapid adoption among independent scientists, driving a sharp turnaround in high-margin service revenues. Restructuring efforts successfully stabilize cash burn at the lower end of the $125-$150 million guidance, extending the cash runway and proving the long-term viability of the automated biology model.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Singular focus on high-throughput autonomous labs (Nebula) which could significantly improve R&D productivity and lower experimental costs.
Strong liquidity position with $373 million in cash, cash equivalents, and marketable securities, and no bank debt as of Q1 2026.
Successful divestiture of the volatile, non-core Biosecurity business, streamlining operations into a single reporting segment.

Key Investment Risks

Severe top-line contraction, with Q1 2026 revenue declining 49% YoY to $19 million.
Persistent, heavy GAAP net losses ($76 million in Q1 2026) and high capital intensity of the autonomous lab infrastructure.
Unproven commercial demand and monetization model for external sales of autonomous lab systems.

Thesis Invalidation Triggers

Securing major, multi-year autonomous lab system sales or strategic partnerships with top-tier biopharma companies.
Achieving Adjusted EBITDA breakeven significantly ahead of current market expectations.
A sudden, material acceleration in Cloud Lab or Datapoints contract research revenues.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.